Industry News

VCA Inc., a leading animal healthcare company in the United States and Canada, will report financial results for its third quarter of 2016 on Wednesday, October 26 th, 2016, at 8:00 a.m. ET. The company will host a conference call and webcast beginning at 9:00 a.m. ET on that day.. The webcast can be accessed by visiting the company’ s website at investor.vca.com."/>
VCA Inc. to Report Third Quarter 2016 Financial Results
XOMA Corporation, a leader in the discovery and development of therapeutic antibodies, provided an update on its ongoing XOMA 358 Phase 2 studies in patients with severe hypoglycemia due to congenital hyperinsulinism and post-bariatric surgery, two rare conditions resulting from abnormal insulin..."/>
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
National Grid and the U.S. It's a follow-up to AOL founder Steve Case's Rise of the Rest tour that passed through..."/>
Life-sciences accelerator program selects 11 startups [The Buffalo News, N.Y.]
Agilent Technologies Inc. today announced the pricing of a series of its senior notes in an aggregate principal amount of $300 million, in an underwritten, registered public offering. The offering is being conducted under an automatic shelf registration statement on file with the Securities and Exchange Commission. The notes will mature in September 2026 and will bear interest at an annual rate of 3.050 percent."/>
Agilent Technologies Prices $300 Million of Senior Notes
Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced that Meenu Chhabra, president and chief executive officer of Proteostasis Therapeutics, will present at the following upcoming investor conferences:. Leerink Partners Rare Disease& Immuno-Oncology Roundtable Series on Wednesday,..."/>
Proteostasis Therapeutics to Present at Upcoming Investor Conferences
Cigna review is resumed, she will recuse herself from further oversight of Anthem's proposed $48 billion purchase of Cigna. Wade, a former employee of Bloomfield-based Cigna whose husband is still employed by the company, was overseeing the state's review of the deal. Before ruling whether the deal would be allowable in Connecticut, the U.S."/>
Insurance Commissioner To Recuse Herself From Anthem-Cigna Review [The Hartford Courant]
Cigna Corp. told investor analysts Wednesday that he and other executives, struggling with financial losses in public health exchanges, had a "good back and forth" recently with President Barack Obama, but he offered no details. David Cordani was among a group of executives to meet with Obama on Monday. Bloomberg reported that Obama met with senior administration officials and industry executives, including Cordani, Humana Inc. CEO Bruce..."/>
Obama, Cigna Officials Talk Obamacare [The Hartford Courant]
Covalon Technologies Ltd., an advanced medical technologies company, today announced the issuance of an aggregate of 70,000 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $2.29 per stock option. About Covalon Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives..."/>
Covalon Announces Issuance of Stock Options
ChromaDex Corp., an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it will showcase a number of industry-advancing health and wellness products and services during this year’ s SupplySide West, October 4 through 8 in Las Vegas. Attendees stopping by booth# P137 will see..."/>
Update: ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016
Viveve Medical, Inc., a medical technology company focused on women's health, today announced that Brigitte Smith has resigned as a director of Viveve's Board of Directors, including from her positions as Chairman of the Board and member of the Compensation Committee and Governance and Nominating Committee. Her resignation will be effective September 30, 2016.. Smith joined the company in 2007 as a member of the Board of Directors of Viveve, Inc., the..."/>
Viveve(R) Announces Resignation of Brigitte Smith From Company Board of Directors
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, today announced changes to the Company’ s executive leadership team and an update on its compliance with Nasdaq’ s listing requirements."/>
Alphatec Holdings Announces Company Updates
Amgen today announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. The data will be presented in posters# P057 and# P058 at the 5 th European Headache and Migraine Trust International Congress in Glasgow, Scotland. "Chronic migraine patients lose more than half of their life to migraines with..."/>
Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
Novavax, Inc., today announced topline data from two clinical trials of its RSV..."/>
Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults
Quorum Health Corporation management will participate in the Credit Suisse Global Credit Products Conference held September 21-23, 2016, at the Fontainebleau Miami Beach in Miami Beach, FL. Management will present at 9:20 a.m. Eastern Time, on September 22, 2016, and the presentation will be available via a live audio webcast. A link to the live audio webcast will be available at the Investor Relations section of the Company’ s website,..."/>
Quorum Health Corporation to Participate in Credit Suisse Credit Products Conference
BioTime, Inc., a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficacy data from the AST-OPC1 SCiSTAR Phase 1/ 2 a clinical study in patients with complete cervical spinal cord injuries at the 55th Annual Scientific Meeting of the International Spinal Cord Society on September 14, 2016.. For additional information on..."/>
BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
Capricor Therapeutics, Inc. today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc., are acting as..."/>
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Pro-Dex, Inc. today announced financial results for its fiscal 2016 fourth quarter and full-year ended June 30, 2016.. Quarter Ended June 30, 2016. Net sales for the three months ended June 30, 2016 increased $1.2 million, or 29%, to $5.3 million from $4.1 million for the three months ended June 30, 2015, due primarily to increased medical device sales, especially in the orthopedic and craniomaxillofacial surgical segments."/>
Pro-Dex, Inc. Announces Fiscal 2016 Fourth Quarter and Full-Year Results
Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced a transition in the business development team at Ocera. Gaurav Aggarwal, M.D., Chief Business Officer of Ocera, is returning to his former role as a biopharmaceutical investor. Akiko Shibata, the former Vice President of Business Operations at Ocera from 2005 to 2013, will be..."/>
Ocera Announces Management Transition
TeamHealth Holdings, Inc., a leading physician services organization, announced the acquisition of the provider operations of EmMed, PC. Based in Bay City, Michigan, EmMed, PC provides care to approximately 44,000 patients each year through staffing and management of the emergency department at McLaren Bay Regional Hospital. "In the changing and dynamic healthcare landscape, TeamHealth will provide the resources and support that we..."/>
TeamHealth Acquires the Provider Operations of EmMed, PC
Cepheid. The presence of binary toxin-producing C. difficile has been linked to increased disease severity, mortality and disease recurrence. 1,2 In addition, strains of C. difficile have been documented that appear to cause disease..."/>
Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market
Veracyte, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor, has posted a draft local coverage determination for the Percepta Bronchial Genomic Classifier. The Palmetto draft LCD posting follows the September 8 posting by Noridian Health Solutions, another participant in the MolDx Program that Palmetto GBA established and administers. The remaining two MolDx Program participating MACs are..."/>
Veracyte Secures Draft Medicare Local Coverage Determination for Percepta® Bronchial Genomic Classifier from Palmetto GBA
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Cantor Fitzgerald& Co. is acting as the sole underwriter for the offering. Aerie intends to use the net proceeds of..."/>
Aerie Pharmaceuticals Announces Public Offering of Common Stock
Ipsen SA, today announced that eight posters regarding the use of Dysport ® in various therapeutic indications have been selected for presentation at the annual meeting of the American Association of Neuromuscular& Electrodiagnostic Medicine being held in New Orleans, Louisiana, September 14– 17, 2016.. "The presentations this year at AANEM demonstrate the continued commitment of..."/>
Ipsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine
Air Methods, America’ s largest air medical provider and helicopter operator, today announced the promotion of Leo Morrissette to senior vice president of aviation operations.. “Leo brings more than 30 years of aviation experience and strategic direction to the leadership team,” said Mike Allen, Air Methods’ president of air medical services.“ This new role is imperative to the future success of our air medical services division. Leo will strengthen our..."/>
Air Methods Named Morrissette Senior Vice President of Aviation Operations
Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Stephen Sundlof, DVM, PhD, Chief Scientific Officer and Executive Vice President, Regulatory Affairs and Quality, will be serving on a panel at the BIO Animal Biotech Summit in Bethesda, Maryland on Thursday, September 22, 2016 at 3.30 pm EDT. The panel discussion, titled "Barriers to Innovation: Regulation and..."/>
Kindred Biosciences to Participate in a BIO Animal Biotech Summit Panel

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary491 Articles
Information Technology487 Articles
Financials316 Articles
Industrials291 Articles
Health Care269 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.